Announcing positive preliminary results from ongoing Phase 1 clinical trial evaluating first-in-class MYB RNA degrader, REM-422, in patients with R/M adenoid cystic carcinoma at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
bit.ly/4ozZes8

Our MYB RNA degrader, REM-422, will be featured in late-breaking oral and poster presentations and in a session on targeting RNA with small molecules at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
➡️ bit.ly/48u70iy

Our CSO, Dom Reynolds, breaks down the science behind Remix’s pioneering new approach to treating difficult to drug diseases by targeting the cellular complexes that process RNA & working upstream of conventional therapeutic approaches.

➡️ More here: bit.ly/3VGrT2o

Data presented in poster sessions at the @theaacr.bsky.social and European Hematology Association Conferences demonstrate the importance of the MYB protein as the driver of diseases like ACC and AML.

Learn more about REM-422 and Remix's ongoing clinical trials: bit.ly/44qEk6D